So next-generation sequencing has enabled us to analyze lots of genes and also more genes at the same time. And in CLL, since we need to analyze for TP53 mutations, it has been a shift from Sanger sequencing to next-generation sequencing in order to detect TP53 mutations. Also, next-generation sequencing has a higher sensitivity compared to Sanger sequencing. And through ERIC, we have a certification system for both Sanger sequencing and for next-generation sequencing...
So next-generation sequencing has enabled us to analyze lots of genes and also more genes at the same time. And in CLL, since we need to analyze for TP53 mutations, it has been a shift from Sanger sequencing to next-generation sequencing in order to detect TP53 mutations. Also, next-generation sequencing has a higher sensitivity compared to Sanger sequencing. And through ERIC, we have a certification system for both Sanger sequencing and for next-generation sequencing. And we see that many labs are more and more certifying for next-generation sequencing. So it’s obvious that this technique will be the gold standard for the future. And here at Karolinska, we use a gene panel where TP53 is included. Also, we have included BTK and PLC gamma-2. So if the referring physician asks for resistance mutations, we can also give reply for these two genes.